INSMED INC Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- INSMED INC stock issued during period, value, new issues for the quarter ending 2025-12-31 was $0.00.
- INSMED INC stock issued during period, value, new issues for the quarter ending 2025-09-30 was -$256.00K, a 100.07% decline year-over-year.
- INSMED INC stock issued during period, value, new issues for the quarter ending 2025-06-30 was $823.54M, a 15.41% increase year-over-year.
- INSMED INC stock issued during period, value, new issues for the quarter ending 2024-12-31 was -$12.00K, a 100.01% decline year-over-year.
- INSMED INC stock issued during period, value, new issues for fiscal 2025 was $823.28M, a 24.06% decline from fiscal 2024.
- INSMED INC stock issued during period, value, new issues for fiscal 2024 was $1.08B, a 611.02% increase from fiscal 2023.
- INSMED INC stock issued during period, value, new issues for fiscal 2023 was $152.47M, a 47.81% decline from fiscal 2022.
- INSMED INC stock issued during period, value, new issues for fiscal 2022 was $292.15M, a 8.25% increase from fiscal 2021.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $823.28M 10-K · filed 2026-02-19 |
| 2025-09-30 | -$256.00K 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $823.54M 10-Q · filed 2026-08-06 | |
| 2024-12-31 | -$12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $1.08B 10-K · filed 2026-02-19 |
| 2024-09-30 | $370.98M 10-Q · filed 2025-10-30 | $1.20B derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $713.57M 10-Q · filed 2025-08-07 | $827.62M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | -$409.00K 10-Q · filed 2025-05-08 | $152.07M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $114.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $152.47M 10-K · filed 2026-02-19 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | |
| 2023-06-30 | $38.01M 10-Q · filed 2024-08-08 | |
| 2022-12-31 | $258.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $292.15M 10-K · filed 2025-02-20 |
| 2022-09-30 | $33.38M 10-Q · filed 2023-10-26 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $269.89M 10-K · filed 2024-02-22 |
| 2021-09-30 | $269.89M 10-Q · filed 2021-10-28 | |
| 2021-06-30 | $269.89M 10-Q · filed 2022-08-04 | |
| 2020-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $245.87M 10-K · filed 2023-02-23 |
| 2020-09-30 | -$47.00K 10-Q · filed 2021-10-28 | |
| 2020-06-30 | $245.91M 10-Q · filed 2021-08-05 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $261.07M 10-K · filed 2021-02-25 |
| 2019-09-30 | -$104.00K 10-Q · filed 2020-10-29 | |
| 2019-06-30 | $261.18M 10-Q · filed 2020-08-06 | |
| 2017-12-31 | $377.66M 10-K · filed 2020-02-25 | |
| 2015-12-31 | $222.94M 10-K · filed 2018-02-23 | |
| 2014-12-31 | $109.01M 10-K · filed 2017-02-23 | |
| 2013-12-31 | $67.02M 10-K · filed 2016-02-25 | |
| 2012-12-31 | $25.66M 10-K · filed 2015-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |